Key PointsQuestionsWhat are the trends in net prices for insulin products, and did those trends change after the introduction of new insulin products, generating savings?FindingsIn this longitudinal study of 2012 to 2019 drug pricing data, after accounting for discounts, net prices of long-acting insulin products faced by payers increased by a mean of 23.6% per year from 2012 to 2014 but decreased by 8.3% from 2015 to 2019, coinciding with the introduction of 3 new long-acting insulin products.MeaningThe entry of new insulin products was followed by decreases in net prices, which lowered spending on long-acting insulins after 2015.